{"links":{"feed":"https://www.erudio.com/reports/magnetismm-7-nct05317416/feed.json","html":"https://www.erudio.com/reports/magnetismm-7-nct05317416","json":"https://www.erudio.com/reports/magnetismm-7-nct05317416.json","markdown":"https://www.erudio.com/reports/magnetismm-7-nct05317416.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"magnetismm-7-nct05317416"}},"request":"https://www.erudio.com/contact?report=magnetismm-7-nct05317416"},"offer":{"cited_clinicians":3,"cited_commentary_sources":5,"verified_hcp_statements":34,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":5},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"magnetismm-7-nct05317416"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=magnetismm-7-nct05317416","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/magnetismm-7-nct05317416","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 34 verified statements · 9 from 3 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-22T15:38:41.146723Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":1},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Progression Free Survival"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":4,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":4,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":6,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":2,"coverage":"discussed","id":"A1","source_count":2,"title":"Treatment duration, placement and sequencing"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":2,"title":"Earlier-use and cross-study development rationale"},{"claim_count":7,"coverage":"discussed","id":"A3","source_count":1,"title":"Community delivery and patient-support constraints"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":12,"cited_clinicians":3,"cited_clinicians_by_role":{"physician, Hematology and oncology":1,"physician, Medical oncology":2},"cited_physicians":3,"cited_sources":6,"claims_by_expression_type":{"comparison":2,"experience":1,"interpretation":3,"opinion":1,"primary_context":1,"question":3,"restatement":4,"uncertainty":4,"unspecified":15},"claims_by_kind":{"protocol_statement":1,"source_observation":33},"clinician_statements":9,"evidence_units":18,"findings":5,"people_cited":6,"people_identity_verified":5,"people_total":6,"screened_sources":13,"verified_claims":34},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":1,"views":1},"limitations":2,"links":{"context":2,"support":5},"ma_question":true,"named_voices":2,"passages":5,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"registry":1}},"title":"Lenalidomide alone: why a clinician questions the post-ASCT maintenance comparator","title_holders":{"cited_claim_ids":["claim-46bb681a1bd43fa21f8f"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"4 statements from 2 speakers in 3 sources, 1 of them a podcast or video","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician"},{"cited_clinicians":2,"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":4,"views":1},"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":3,"passages":6,"sources":4,"sources_by_kind":{"commentary":1,"media":2,"registry":1}},"title":"Maintenance: most clinicians ask how long; one asks about OS and sequencing","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-efc940a6c2d26d61e2be"],"clause":"one asks about OS and sequencing","holders":1},"cited_claim_ids":["claim-efc940a6c2d26d61e2be","claim-ec73bdb93e9bb2d5e960"],"clinicians":true,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"7 statements from 3 speakers in 4 sources, 2 of them podcasts or videos","holder_line":"2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one asks about OS and sequencing”"},{"cited_clinicians":1,"id":"F4","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":5,"views":1},"limitations":5,"links":{"context":2,"support":10},"ma_question":true,"named_voices":2,"passages":5,"sources":2,"sources_by_kind":{"media":2}},"title":"Earlier use: a speaker weighs durability vs toxicity; a clinician supports trials","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-9cf7a32117fe0d3bc493"],"clause":"a clinician supports trials","holders":1},"cited_claim_ids":["claim-191564281e3a8baca7ef","claim-56b1469aa7b79bfeeb00","claim-0c15476c1ac1593389e8","claim-a9ec0b7356b1d13499f2-7d37ab9d","claim-0db4015a24d36b52ce96-5f2cbb19","claim-148d999aa0b41c083b0e"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"8 statements from 2 speakers in 2 sources, all podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view; 1 of the 2 holds its caveat, “a clinician supports trials”"},{"cited_clinicians":1,"id":"F2","population":"beyond","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":0,"views":1},"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Elranatamab: where speakers split on relative neuropathy risk","title_holders":{"cited_claim_ids":["claim-314813b661e90141c559","claim-f1728c780577e84111f3","claim-6e0b374fbf2940011cbc"],"clinicians":false,"holders":2,"sides":[{"cited_claim_ids":["claim-314813b661e90141c559"],"holders":1},{"cited_claim_ids":["claim-f1728c780577e84111f3","claim-6e0b374fbf2940011cbc"],"holders":1}],"speakers":2,"view":"split"},"evidence_line":"5 statements from 2 speakers in 1 source","holder_line":"2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other"},{"cited_clinicians":0,"id":"F5","population":"beyond","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":7,"views":0},"limitations":4,"links":{"context":0,"support":8},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Local care: what speakers say","evidence_line":"7 statements from 1 speaker in 1 source, a podcast or video"}],"open_question":{"basis":"From finding F1 (4 statements from 2 speakers in 3 sources)","cited_claim_ids":["claim-e0a0460787343a2a7a9f","claim-bbf5c2f9daa7e6921e6c","claim-46bb681a1bd43fa21f8f","claim-b1808bd86159fe5906e6"],"finding_ids":["F1"],"question":"What do clinicians say about whether lenalidomide alone remains the right comparator for elranatamab maintenance in MagnetisMM-7 after autologous transplantation in newly diagnosed multiple myeloma, versus daratumumab–lenalidomide or possibly isatuximab–lenalidomide?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One X account questions the contemporary relevance of the control arm"},{"id":"section-2","level":2,"title":"An X account and an interview speaker leave treatment duration open"},{"id":"section-3","level":2,"title":"One speaker proposes a T-cell-fitness hypothesis; another cites prior work as development rationale"},{"id":"section-4","level":2,"title":"Beyond the trial population"},{"id":"section-5","level":3,"title":"The X safety exchange distinguishes clinical impressions from comparative evidence"},{"id":"section-6","level":3,"title":"One speaker links community access to delivery pathways; unattributed remarks describe a support barrier"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F3","shared_claims":2}],"id":"T1","label":"Primary endpoint: Progression Free Survival"},{"findings":[{"id":"F3","shared_claims":3}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-22T15:38:41.146723Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-22T15:51:51Z","record_hash":"55872e406b3464dbd640ce73a614820ae13bb1a47f1f75f07071d2fc639561d0","release_hash":"67a580e655dd94086b2777c68ef0b6e36c11f74c1d88be464fe53470aa8c8979","report_id":"erudio-nct05317416","run_id":"60dad341-b61b-489f-be2d-98dd9180756e","schema_version":"5.0","slug":"magnetismm-7-nct05317416","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist reads MagnetisMM-7 as challenging maintenance practice, but considers Dara-R arguably more current than lenalidomide alone, with Isa-R only a possibility. In broader safety discussion, another speaker perceives more neuropathy, myalgias and skin reactions with elranatamab than with other bispecifics in practice; that oncologist cites broadly similar reported neurologic rates for elranatamab and teclistamab, noting prior-treatment confounding. The clinicians cited leave duration unresolved; neither comparison establishes maintenance-specific safety, and the sources reviewed for this edition provide no trial outcomes.","examples":[],"meta_description":"13 sources screened · 34 verified statements (9 from clinicians verified by NPI or staff page) from 6 sources · 5 findings. Updated Nov 22, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-22T15:51:51Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":13},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","20 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 38 sources about other trials or topics are not included; discussion that refers to the trial only by a name it shares with other things may be missing.","The sources reviewed for this edition are selected public discussions, not a representative sample of HCP opinion. One X thread and four video sources underpin this narrative; multiple statements or reposts should not be counted as independent clinicians.","Discussion that does not name the trial, uses short acronyms or contains other transcription variants may be missing. An issue not discussed here may nevertheless be discussed elsewhere.","A standalone protocol document and an exact-trial publication were not identified for this edition. The materials do not provide MagnetisMM-7 outcome data with which to test the expressed expectations or concerns.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The comparative safety impressions and reported neurologic rates lack sufficient population, timing and study detail to establish comparative safety in post-transplant maintenance.","Some panel remarks cannot be assigned to a named speaker and may have been made by a named participant already represented elsewhere in the discussion.","General earlier-line and community-delivery observations do not establish MagnetisMM-7 efficacy, toxicity rates, dosing schedules or service requirements."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":1,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":5,"methods":1},"count":6,"evidence_window":{"end":"2026-11-01","start":"2022-10-06"},"retrieval_snapshot":"2026-11-22T15:11:42.949812Z","timeline":[{"count":1,"week":"2022-W40"},{"count":1,"week":"2023-W05"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2026-W26"},{"count":1,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05317416:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05317416:context","quote_policy":"short_quote_link_out"},{"id":"openfda:f6fea598-ff58-4a20-b5e8-8a51f37d8beb:20260914","quote_policy":"short_quote_link_out"},{"id":"openfda:84d9dec7-9250-4dbd-9a0d-23e75f111892:20261029","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:1048d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1512335303884824580:b48ea074-9478-4d9b-862d-3f67e19cbd73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1601668747596484609:b59d9709-622a-4e93-a6e1-05a69f0db8f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1763622335196598656:9da97cd0-660a-4b20-b37a-72f95df8b08d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887742078009983003:3569d9e3-cd1f-42db-be28-7cca30b6924c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887872374797746491:3f7e49b8-f480-482d-a337-d74b6f6d25cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997631361926996306:17e56d11-fd28-437f-9574-ea23d9f86bc3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045252488719409191:7c70a034-0462-4ad3-ba7e-308d146b5319","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116908306404978934:aa3049ec-b3e7-42ba-9c73-1fc7f1b3c0f3","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:KlEEsHeeYmw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SmwqbCPiVf8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:kuuBdOvU4xQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:wMl-c4kgPtQ","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":8,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":13},"count":13,"evidence_window":{"end":"2026-11-01","start":"2022-04-08"},"retrieval_snapshot":"2026-11-22T15:11:42.949812Z","timeline":[{"count":1,"week":"2022-W14"},{"count":1,"week":"2022-W40"},{"count":1,"week":"2022-W49"},{"count":1,"week":"2023-W05"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2024-W09"},{"count":2,"week":"2025-W06"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W16"},{"count":1,"week":"2026-W26"},{"count":1,"week":"2026-W44"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":8,"x_video":0,"youtube":25}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Elrexfio"],"label":"elranatamab","slug":"elranatamab"},{"brand_names":["Revlimid"],"label":"lenalidomide","slug":"lenalidomide"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"MagnetisMM-7","aliases":["MagnetisMM-7","Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION"],"brief_title":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Multiple Myeloma"],"display_condition":"newly diagnosed multiple myeloma after autologous stem-cell transplantation","display_interventions":[["elranatamab"]],"enrollment":{"count":854,"type":"ACTUAL"},"interventions":[{"name":"Elranatamab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Lenalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Lenalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Elranatamab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05317416","official_title":"A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2027-08-04","type":"ESTIMATED"},"primary_endpoints":[{"description":"Progression Free Survival assessed by Blinded Independent Central review per IMWG response criteria","measure":"Progression Free Survival","timeFrame":"Assessed for up to approximately 5 years"}],"registered_date":{"date":"2022-04-07","type":"ACTUAL"},"registry_last_updated":"2026-04-16","registry_url":"https://clinicaltrials.gov/study/NCT05317416","short_name":"MagnetisMM-7","short_name_basis":"registry_acronym","sponsor":"Pfizer","start_date":{"date":"2022-03-25","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"C1071007","type":"sponsor_study_id"},{"domain":"Alias Study Number","id":"MagnetisMM-7","type":"other"},{"domain":"CTIS (EU)","id":"2023-508897-27-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}